Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
Diabetes Care · 01.06.2026 · 49 (6) · 1115-1123
DOI: 10.2337/dc25-2973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 20.05.2026. Verfasst von Katherine G Young und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, U.K. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD. RESEARCH DESIGN AND METHODS We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020. RESULTS Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63–0.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model–predicted 5-year absolute HF benefit with SGLT2i ranged from <0.1% to 14.1% (median 1.0% [interquartile range 0.6–1.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD. CONCLUSIONS The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, U.K.
- Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K.
- Division of Diabetes, Endocrinology and Reproductive Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, U.K.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K.
ORCID-Profile: Katherine G Young, Andrew P McGovern, Rhian Hopkins, Thijs T Jansz, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, Naveed Sattar, Beverley M Shields, John M Dennis
Förderung
- Medical Research Council
Zitieren
APA
Young, K. G., McGovern, A. P., Hopkins, R., Jansz, T. T., Cardoso, P. M., Holman, R. R., Pearson, E. R., Hattersley, A. T., Jones, A. G., Docherty, K., Sattar, N., Shields, B. M., Dennis, J. M., & MASTERMIND Consortium (2026). Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care, 49(6), 1115-1123. https://doi.org/10.2337/dc25-2973
Vancouver
Young KG, McGovern AP, Hopkins R, Jansz TT, Cardoso PM, Holman RR, et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care. 2026;49(6):1115-1123. doi:10.2337/dc25-2973
BibTeX
@article{Young2026,
author = {Young, Katherine G and McGovern, Andrew P and Hopkins, Rhian and Jansz, Thijs T and Cardoso, Pedro M and Holman, Rury R and Pearson, Ewan R and Hattersley, Andrew T and Jones, Angus G and Docherty, Kieran and Sattar, Naveed and Shields, Beverley M and Dennis, John M and MASTERMIND Consortium, MASTERMIND Consortium},
title = {Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study},
journal = {Diabetes Care},
year = {2026},
volume = {49},
number = {6},
pages = {1115--1123},
doi = {10.2337/dc25-2973}
}
EUVIMED